June U.S. healthcare govt grants, clinical trials & NIH outlays increase vs May, says Baird
rarrarorro

U.S. outlays from the National Institutes of Health (NIH), clinical trials, and healthcare government grants for June increased over May and Y/Y, according to Baird Equity Research.
NIH outlays increased ~8% YY in June and 6% vs. May to $3.69B, after 13% YY growth and a 14% YY decline in May and April, respectively. 
Baird estimates NIH exposure for tools names as follows: (NSTG) ~20%+, (ILMN) ~15%-20%, (TECH) ~15%, (PKI) ~6%, (TMO) ~5%, (AVTR) ~5%, (A) ~1%-2%, (WAT) ~1%. 
Clinical trials listed on clinicaltrials.gov monthly increased ~1% in June to 420,104, a rise of 10% Y/Y. Baird believes if growth continues on its YTD trajectory, this would imply ~440,330 registered clinical trials at 2022-end, a ~10.3% YY increase, ~in line with 2021âs ~10.2% YY growth.
Illumina (ILMN) currently has the most clinical trials, at 354, followed by NanoString (NSTG) at 141.
As of June-end, 35,710 clinical trials were funded by the NIH, 129,734 were funded by industry, 7,851 were funded by other U.S. federal agencies, and 250,502 were funded by other sources.
U.S. government grants increased ~1% vs. May-end and ~7% YY. The fastest-growing keyword among grants during June was "cancer," +0.9% vs. May-end.